艾伯维公司近日公布其长效胰淀素类似物ABBV-295的一期多剂量递增试验数据,结果显示该药物表现出良好的耐受性。与安慰剂组相比,ABBV-295治疗组患者体重出现剂量依赖性显著下降,且减重幅度具备临床意义。
此次数据为ABBV-295作为慢性体重管理差异化疗法的后续开发提供了有力支持。该药物有望为肥胖症治疗领域带来新的突破。
艾伯维公司近日公布其长效胰淀素类似物ABBV-295的一期多剂量递增试验数据,结果显示该药物表现出良好的耐受性。与安慰剂组相比,ABBV-295治疗组患者体重出现剂量依赖性显著下降,且减重幅度具备临床意义。
此次数据为ABBV-295作为慢性体重管理差异化疗法的后续开发提供了有力支持。该药物有望为肥胖症治疗领域带来新的突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.